CH 138
Latest Information Update: 18 May 1998
Price :
$50 *
At a glance
- Originator Celltech Group
- Developer Bristol-Myers Squibb; Celltech Group
- Class Antirheumatics
- Mechanism of Action Metalloprotease inhibitors; Peptide hydrolase inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Rheumatoid arthritis
Most Recent Events
- 18 May 1998 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 18 May 1998 Discontinued-Preclinical for Rheumatoid arthritis in United Kingdom (Unknown route)
- 20 Feb 1998 Preclinical development for Cancer in USA (Unknown route)